Home » Posts tagged with » Massachusetts
Epizyme gets FDA priority review for TAZVERIK in follicular lymphoma

Epizyme gets FDA priority review for TAZVERIK in follicular lymphoma

Epizyme has been granted priority review by the US Food and Drug Administration (FDA) for the use of TAZVERIK (tazemetostat) in relapsed or refractory follicular lymphoma (FL). As per the new drug application (NDA) that has been accepted by the FDA, the Massachusetts-based biopharma company is seeking the accelerated approval of the methyltransferase inhibitor for […]

Lyra Therapeutics raises $30m for chronic rhinosinusitis drug candidates

Lyra Therapeutics has raised $30 million in a Series C financing round to advance its lead product candidates for the treatment of chronic rhinosinusitis (CRS). Known as an inflammatory disease of the paranasal sinuses, chronic rhinosinusitis is said to affect around 14 million people in the US. The lead product candidates of the US-based clinical-stage […]

Continue reading …
Merck acquires ArQule for $2.7bn to further diversify oncology pipeline

Merck acquisition of ArQule : Merck has completed its previously announced acquisition of ArQule for $20 per share or about $2.7 billion as per the latest pharma acquisition news. The pharma giant announced the deal in December 2019 in a move to further diversify its oncology pipeline with the Massachusetts-based ArQule focused on developing kinase […]

Continue reading …
Roche signs $2.85bn deal with Sarepta for SRP-9001 DND gene therapy

Roche has signed a licensing deal worth up to $2.85 billion with Sarepta Therapeutics for the exclusive ex-US commercial rights to the latter’s SRP-9001 (AAVrh74.MHCK7.micro-dystrophin), an investigational gene therapy for Duchenne muscular dystrophy (DMD). As per the agreement terms, Sarepta Therapeutics will get an upfront payment made up of $750 million in cash and $400 […]

Continue reading …
Glaukos closes Avedro acquisition to expand corneal health franchise

Glaukos acquisition of Avedro : Glaukos Corporation, a California-based ophthalmic medical technology and pharmaceutical company, has completed its previously announced acquisition of Avedro. Based in Waltham, Massachusetts, Avedro is a hybrid ophthalmic pharmaceutical and medical technology company, which is focused on treating corneal disease and disorders and enhancing vision to decrease dependency on eyeglasses or […]

Continue reading …
CD&R to acquire Cynosure medical aesthetics business from Hologic for $205m

Clayton, Dubilier & Rice (CD&R), a New York-based private equity firm, has signed an all-cash deal worth $205 million to acquire Cynosure, a medical aesthetics technology company, from US medical device company Hologic. Based in Massachusetts, Cynosure provides medical aesthetic treatment systems for plastic surgeons, dermatologists, medical spas and other healthcare practitioners. Cynosure’s product portfolio […]

Continue reading …
Roche to acquire US biotech company Promedior for $1.4bn

Roche acquisition of Promedior : Swiss drugmaker Roche has agreed to acquire Massachusetts-based biotech company Promedior in a deal worth up to $1.39 billion, as per the latest pharma acquisition news. The acquisition will give full rights for the Swiss pharma giant to Promedior’s portfolio of molecules targeting serious fibrotic diseases, including PRM-151, which holds […]

Continue reading …
WIRB-Copernicus acquires clinical trial consultant Waife & Associates

WIRB-Copernicus Group (WCG), a clinical services organization, said that its clinical services division has acquired Waife & Associates (W&A), a provider of management consulting services for biopharma clinical research clients. Financial terms of the acquisition were not disclosed by the parties. Waife & Associates is engaged in making clinical development more efficient and productive by […]

Continue reading …
MicroMedicine to introduce new white blood cell isolation technology at SITC annual conference

MicroMedicine, a US life sciences technology company, will launch Sorterra Cell Isolation System, a white blood cell isolation technology, at the 34th Society for Immunotherapy of Cancer (SITC) annual conference to be held from November 6-10 in National Harbour, Maryland. Sorterra Cell Isolation System will separate white blood cells from human peripheral blood preserving sample […]

Continue reading …
ProTom Radiance 330 proton therapy system bags FDA 510(k) Clearance

ProTom International has been given 510(k) clearance from the US Food and Drug Administration (FDA) for its Radiance 330 proton therapy system installed at the Massachusetts General Hospital (MGH) in Boston. According to the proton therapy technology manufacturer, the installed Radiance 330 proton therapy system is a compact, single-room system, which features an advanced pencil […]

Continue reading …
Page 1 of 212